2699608-30-3

Clarithromycin-13C-d3 is intended for use as an internal standard for the quantification of clarithromycin (Item No. 19455) by GC- or LC-MS. Clarithromycin is a polyketide synthase-derived semisynthetic macrolide antibiotic.1,2,3 It is active against methicillin-susceptible, but not methicillin-resistant, S. aureus (MIC50s = 0.06 and >128 µg/ml), S. pyogenes, L. monocytogenes, and B. pertussis (MIC50 = 0.015, 0.25, and ≤0.008 µg/ml, respectively), among others.1 Clarithromycin (25 mg/kg) decreases the number of colony-forming units (CFUs) in the spleen in a mouse model of M. avium infection.4 Formulations containing clarithromycin have been used in the treatment of bacterial infections and, when used in combination with other antibiotics, in the treatment of H. pylori.WARNING This product is not for human or veterinary use.

[1] D J HARDY. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.[J]. Antimicrobial Agents and Chemotherapy, 1988, 32 11: 1710-1719. DOI: 10.1128/aac.32.11.1710
[2] WILSON D N. The A-Z of bacterial translation inhibitors.[J]. Critical Reviews in Biochemistry and Molecular Biology, 2009, 44 6: 393-433. DOI: 10.3109/10409230903307311
[3] JIAQUAN WU. Biochemical Analysis of the Substrate Specificity of the β-Ketoacyl-Acyl Carrier Protein Synthase Domain of Module 2 of the Erythromycin Polyketide Synthase†[J]. Biochemistry Biochemistry, 2004, 43 51: 16301-16310. DOI: 10.1021/bi048147g
[4] P B FERNANDES. In vitro and in vivo activities of clarithromycin against Mycobacterium avium.[J]. Antimicrobial Agents and Chemotherapy, 1989, 33 9: 1531-1534. DOI: 10.1128/aac.33.9.1531